Recent News and Articles on the Keywords: alzheimers + stops + brain  Related to the article below (Last Update: 8/7/2008)

Too soon to celebrate Alzheimer's drug New Statesman, UK - ... tangles that destroy the nerve cells linked to memory and then other parts of the brain as the disease progresses. Rember can stop this happening. ... HealthNews International Conference on Alzheimer?s Disease Concludes HealthNews, CA - Scientists hope that the next generation of therapies will be disease modifying; that they will slow or stop the brain cell death and loss of function ... China Daily Exercise Stops Brain Shrinking in Alzheimer's Patients The Money Times, India - Jul 28, 2008 The study, which is believed to be the first to compare brain volume and fitness in Alzheimer's patients, looked at the relationship between fitness and ... New drug boosts brain function in Alzheimer's patients ABC Online Health problems, personality raise Alzheimer's risk, studies show Dallas Morning News Health: Alzheimer's Breakthrough CBS 3 UK Express - Press and Journal all 678 news articles » Alzheimers a distant memory with wonder drug Melbourne Herald Sun, Australia - Jul 30, 2008 A NEW drug can halt the progress of Alzheimer's disease, a group of scientists claimed yesterday. A daily capsule of Rember stops the disease progressing by ... ? Daily Pill Said To Stop Alzheimer's Consumer Affairs New drug discovered to stop effects of Alzherimer's Courier Mail New drug may be first ever to stop Alzheimers Special Broadcasting Service Best Syndication - Slashdot all 630 news articles » Antibiotics: Doctors told to stop indiscriminate prescribing What Doctors Don't Tell You, UK - The Poisoned Brain - Big Pharma has spectacularly failed with Alzheimer?s. This failure was underscored recently when Britain?s National Institute for ... A metal trap to stop Alzheimer's Chemistry World, UK - Jul 30, 2008 These insoluble aggregates remain in the brain and appear to play a critical role in the formation of the distinctive Alzheimer's plaques. ... Canada.com Eli Lilly to release Alzheimer's drug study data Forbes, NY - Jul 30, 2008 Alzheimer's is an irreversible, fatal disease. It involves the formation of lesions in the brain called plaques and tangles. Scientists believe they poison ... Alzheimer Disease Plaques Seen With Conventional MRI in Animal ... MarketWatch New hope for Alzheimer's diagnosis Hospital Healthcare Europe Conventional MRI And Computer Analysis Could Be Used To Detect ... Medical News Today eFluxMedia all 106 news articles »  LLY Alzheimer's Research Holds Promise TIME - Jul 31, 2008 When it comes to Alzheimer's disease, there hasn't been much to celebrate in recent years. Efforts to develop a vaccine against the brain disorder have ... The Age Stop the brain drain with a little mental gymnastics The Canberra Times, Australia - Jul 15, 2008 Mental activity has been found to delay the onset of the degenerative brain diseases, such as Huntington's, Alzheimer's and Parkinson's, in large population ... Want to stop your brain deteriorating with age? It's all in the mind Daily Mail all 10 news articles » Health Front and Center Publishers Weekly, NY - Aug 4, 2008 One of many grim statistics of the Iraq war is the number of soldiers returning home with brain injuries (more than 300000 at last count, according to the ...

MW01-5-188WH stops brain cell degeneration in Alzheimer's disease

Researchers at Northwestern University have developed a novel orally administered compound specifically targeted to suppress brain cell inflammation and neuron loss associated with Alzheimer's disease.

As described in the Journal of Neuroscience, the compound, called MW01-5-188WH, selectively inhibits production of pro-inflammatory proteins called cytokines by glia, important cells of the central nervous system that normally help the body mount a response, but are overactivated in certain neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, stroke and traumatic brain injury.

The compound was designed and synthesized in the laboratory of D. Martin Watterson at Northwestern University Feinberg School of Medicine, using a synthetic chemistry platform developed in his lab by researchers at the Northwestern University Center for Drug Discovery and Chemical Biology ( CDDCB ) for the rapid discovery of new potential therapeutic compounds.

The efficacy and safety of the compound in an animal model of Alzheimer's disease was evaluated in collaboration with Linda J. Van Eldik, co-director of the CDDCB,

Besides providing a lead compound for drug development, the study has important implications for drug discovery in neurodegenerative diseases in general because it provides proof of concept that targeting over-production of cytokines by activated glia is a viable approach that has the potential to modulate disease onset and progression, the researchers said.

Decline of cognitive functions linked to the part of the brain called the hippocampus is a clinical hallmark of Alzheimer's disease. The report demonstrates that targeting excessive glial activation can suppress brain inflammation and neuron dysfunction in the hippocampus and protect against cognitive decline in an animal model.

Neuron dysfunction can lead to further glia activation and contribute to further exacerbation of the disease process. The Northwestern researchers found that 188WH and related compounds slowed or reversed the progression of the neuroinflammatory cascade and reduced human amyloid beta-induced glia activation in a mouse specially designed to develop many of the signs of Alzheimer's disease, including neuroinflammation, neuronal and synaptic degeneration and behavioral deficits.

The compound also restored normal levels of markers of synaptic dysfunction in the hippocampus, the area of the brain that helps regulate memory and is gradually destroyed in neurodegenerative diseases such as Alzheimer's. Treatment with the compound also attenuated Alzheimer's-like behavioral deficits in the mice that are due to injury to the hippocampus.

While previous research by the authors and many other investigators in the field has linked plaques, tangles and neuronal injury to synaptic dysfunction and cognitive decline, the direct linkage of glia to these processes and their potential as a selective target for new therapies has not previously been implicated so directly.

There are three key aspects of the report, Watterson said.

" First, a novel compound for development into a new class of Alzheimer's disease therapeutics that target disease has been described. Second, an innovative approach was used for the rapid and cost-effective discovery of orally bioavailable, safe and efficacious compounds, and this approach can be extended to other disease areas," Watterson said.

" Third, the design, synthesis and in vivo analyses were carried out by a new generation of young scientists trained in our educational program to instruct the next generation of interdisciplinary scientists," Watterson said.

Source: Northwestern University,2006